{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T13:15:29Z","timestamp":1726406129927},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1991,10,1]],"date-time":"1991-10-01T00:00:00Z","timestamp":686275200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutisch Weekblad Scientific Edition"],"published-print":{"date-parts":[[1991,10]]},"DOI":"10.1007\/bf01988874","type":"journal-article","created":{"date-parts":[[2005,8,4]],"date-time":"2005-08-04T14:58:08Z","timestamp":1123167488000},"page":"189-197","source":"Crossref","is-referenced-by-count":4,"title":["Controlling cancer chemotherapy-induced emesis"],"prefix":"10.1007","volume":"13","author":[{"given":"C.","family":"Seynaeve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. H. M.","family":"De Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01988874_CR1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0277-5379(83)90418-2","volume":"19","author":"A Coates","year":"1983","unstructured":"Coates A, Abraham S, Kaye SB, et al. On the receiving end. Patients perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203\u20138.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF01988874_CR2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/1097-0142(19890201)63:3<604::AID-CNCR2820630334>3.0.CO;2-2","volume":"63","author":"RR Love","year":"1989","unstructured":"Love RR, Leventhal H, Easterling DV, Nerenz DR. Side effects and emotional distress during cancer chemotherapy. Cancer 1989;63:604\u201312.","journal-title":"Cancer"},{"issue":"Suppl 1","key":"BF01988874_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198300251-00002","volume":"25","author":"J Laszlo","year":"1983","unstructured":"Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 1983;25(Suppl 1):1\u20137.","journal-title":"Drugs"},{"key":"BF01988874_CR4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0277-5379(89)90143-0","volume":"25","author":"BM Cantwell","year":"1989","unstructured":"Cantwell BM, Carmichael J, Mannix KA, Harris AL. Chemotherapy-induced emesis may exacerbate the nephrotoxicity of combined ifosfamide\/mesna and cisplatin chemotherapy. Eur J Cancer Clin Oncol 1989;25:917\u20138.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF01988874_CR5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/07357908809080656","volume":"6","author":"PB Jacobsen","year":"1988","unstructured":"Jacobsen PB, Redd WH. Development and management of chemotherapy related anticipatory nausea and vomiting. Cancer Invest 1988;6:329\u201336.","journal-title":"Cancer Invest"},{"key":"BF01988874_CR6","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/cncr.1984.53.s10.2267","volume":"53","author":"GR Morrow","year":"1984","unstructured":"Morrow GR. The assessment of nausea and vomiting. Past problems, current issues and suggestions for future research. Cancer 1984;53:2267\u201375.","journal-title":"Cancer"},{"key":"BF01988874_CR7","first-page":"1527","volume":"63","author":"DD Hoff Van","year":"1979","unstructured":"Van Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects ofcis-dichloro-diammineplatinum(II) in man. Cancer Treat Rep 1979;63:1527\u201331.","journal-title":"Cancer Treat Rep"},{"key":"BF01988874_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.1987.5.1.141","volume":"5","author":"F Roila","year":"1987","unstructured":"Roila F, Tonato M, Basurto C, et al. Antiemetic activity of high dose of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients. J Clin Oncol 1987;5:141\u20139.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR9","unstructured":"De Mulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron versus high-dose metoclopramide in the prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med (in press)."},{"key":"BF01988874_CR10","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/1097-0142(19880415)61:8<1508::AID-CNCR2820610806>3.0.CO;2-H","volume":"61","author":"KS Shridhar","year":"1988","unstructured":"Shridhar KS, Donelly E. Combination antiemetics for cisplatin chemotherapy. Cancer 1988;61:1508\u201317.","journal-title":"Cancer"},{"key":"BF01988874_CR11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/00003088-198611060-00001","volume":"11","author":"EM McGovern","year":"1986","unstructured":"McGovern EM, Grevel S, Bryson SM. Pharmacokinetics of high-dose metoclopramide in cancer patients. Clin Pharmacokinet 1986;11:415\u201324.","journal-title":"Clin Pharmacokinet"},{"key":"BF01988874_CR12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00435842","volume":"23","author":"M Marty","year":"1989","unstructured":"Marty M, Droz JP, Pouillart P, et al. GR38032F, a 5-HT3 receptor antagonist, in the prophylaxis of acute cisplatin induced nausea and vomiting. Cancer Chemother Pharmacol 1989;23:389\u201391.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF01988874_CR13","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.1989.7.11.1693","volume":"7","author":"F Roila","year":"1989","unstructured":"Roila F, Tonato M, Basurto C, et al. Protection from nausea and vomiting in cisplatin treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine. J Clin Oncol 1989;7:1693\u2013700.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.1985.3.2.245","volume":"3","author":"SB Strum","year":"1985","unstructured":"Strum SB, McDermed JE, Liponi DE. High-dose metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced emesis. J Clin Oncol 1985;3:245\u201351.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000226385","volume":"43","author":"F Cognetti","year":"1986","unstructured":"Cognetti F, Carlini P, Pinnaro P, et al. Maintenance of antiemetic effect of a MCP\/Dex combination during subsequent cisplatin courses. Oncology 1986;43:292\u20134.","journal-title":"Oncology"},{"key":"BF01988874_CR16","first-page":"257","volume":"5","author":"RW D'Acquisto","year":"1986","unstructured":"D'Acquisto RW, Tyson LB, Gralla RJ, et al. The influence of a chronic high alcohol intake on cisplatin induced nausea and vomiting. Proc ASCO 1986;5:257.","journal-title":"Proc ASCO"},{"key":"BF01988874_CR17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1200\/JCO.1989.7.6.700","volume":"7","author":"PJ Hesketh","year":"1989","unstructured":"Hesketh PJ, Murphy WK, Lester EP, et al. GR38032F: a novel compound effective in the prevention of acute induced emesis. J Clin Oncol 1989;7:700\u20135.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR18","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/1097-0142(19850615)55:12<2766::AID-CNCR2820551207>3.0.CO;2-7","volume":"55","author":"GR Morrow","year":"1985","unstructured":"Morrow GR. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 1985;55:2766\u201370.","journal-title":"Cancer"},{"key":"BF01988874_CR19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0140-6736(82)92625-3","volume":"1","author":"AL Harris","year":"1982","unstructured":"Harris AL. Cytotoxic-therapy induced vomiting is mediated via enkephalin pathways. Lancet 1982;1:714\u20136.","journal-title":"Lancet"},{"key":"BF01988874_CR20","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1200\/JCO.1985.3.10.1400","volume":"3","author":"JE McDermed","year":"1985","unstructured":"McDermed JE, Cohen JL, Joseph C, Strum SB. Clinical pharmacokinetics of high-dose metoclopramide in cancer patients receiving cisplatin therapy. J Clin Oncol 1985;3:1400\u20138.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/aja.1001680407","volume":"168","author":"WJM Hrushesky","year":"1983","unstructured":"Hrushesky WJM. The clinical applications of chronobiology to oncology. Am J Anat 1983;168:519\u201342.","journal-title":"Am J Anat"},{"key":"BF01988874_CR22","first-page":"1487","volume":"68","author":"JH Fetting","year":"1982","unstructured":"Fetting JH, Grochow LB, Folstein MF, et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982;68:1487\u201393.","journal-title":"Cancer Treat Rep"},{"key":"BF01988874_CR23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1200\/JCO.1989.7.1.108","volume":"6","author":"MG Kris","year":"1989","unstructured":"Kris MG, Gralla RJ, Tyson LB, Clark RA. Controlling delayed vomiting: double blind randomised trial comparing placebo, dexamethasone alone and metoclopramide and dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;6:108\u201314.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR24","first-page":"555","volume":"70","author":"N Olver","year":"1986","unstructured":"Olver N, Simon RM, Aisner J. Antiemetic studies: a methodological discussion. Cancer Treat Rep 1986;70: 555\u201363.","journal-title":"Cancer Treat Rep"},{"key":"BF01988874_CR25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.1984.2.5.484","volume":"2","author":"JL Pater","year":"1984","unstructured":"Pater JL, Willan AR. Methodologic issues in trial of anti-emetics. J Clin Oncol 1984;2:484\u20137.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR26","first-page":"1427","volume":"68","author":"S Frytak","year":"1984","unstructured":"Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-tetrahydrocannabinol in cancer patients. Cancer Treat Rep 1984;68:1427\u201331.","journal-title":"Cancer Treat Rep"},{"issue":"Suppl 1","key":"BF01988874_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00003495-198300251-00005","volume":"25","author":"G Wampler","year":"1983","unstructured":"Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy induced emesis. Drugs 1983;25(Suppl 1):35\u201351.","journal-title":"Drugs"},{"key":"BF01988874_CR28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00000441-198701000-00008","volume":"293","author":"JB Craig","year":"1987","unstructured":"Craig JB, Powell BL. Review: the management of nausea and vomiting in clinical oncology. Am J Med Sci 1987;293:34\u201344.","journal-title":"Am J Med Sci"},{"key":"BF01988874_CR29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM198110153051601","volume":"305","author":"RJ Gralla","year":"1981","unstructured":"Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomised trials with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. N Engl J Med 1981;305:905\u20139.","journal-title":"N Engl J Med"},{"key":"BF01988874_CR30","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM198408303110901","volume":"311","author":"M Markman","year":"1984","unstructured":"Markman M, Scheidler V, Ettinger D, Quaskey S, Mellits E. Anti-emetic efficacy of dexamethasone. Randomised, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 1984;311:1549\u201352.","journal-title":"N Engl J Med"},{"key":"BF01988874_CR31","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/1097-0142(19871101)60:9<2165::AID-CNCR2820600908>3.0.CO;2-C","volume":"60","author":"BI Carr","year":"1987","unstructured":"Carr BI, Blayney DW, Goldberg DA, et al. High doses of prochlorperazine for cisplatin-induced emesis. Cancer 1987;60:2165\u20139.","journal-title":"Cancer"},{"key":"BF01988874_CR32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/bmj.290.6468.604","volume":"290","author":"D Cunningham","year":"1985","unstructured":"Cunningham D, Soukop M, Gilchrist NL, et al. Randomised trial of intravenous high-dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs. Br Med J 1985;290:604\u20136.","journal-title":"Br Med J"},{"key":"BF01988874_CR33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00000421-198808000-00012","volume":"11","author":"GA Saab","year":"1988","unstructured":"Saab GA, Shamseddine A. Prolonged chlorpromazine infusion as antiemetic in patients on daily cisplatin infusion. Am J Clin Oncol 1988;11:470\u20133.","journal-title":"Am J Clin Oncol"},{"key":"BF01988874_CR34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/106002808501900207","volume":"19","author":"RJ Cersosimo","year":"1985","unstructured":"Cersosimo RJ, Bromer R, Hoffer S, et al. The antiemetic activity of droperidol administered by intramuscular injection during cisplatin chemotherapy, a pilot study. Drug Intell Clin Pharm 1985;19:118\u201321.","journal-title":"Drug Intell Clin Pharm"},{"key":"BF01988874_CR35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1200\/JCO.1984.2.7.782","volume":"2","author":"SM Grunberg","year":"1984","unstructured":"Grunberg SM, Gala KV, Lampenfield M, et al. Comparison of the antiemetic efficacy of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in randomized double-blind crossover study. J Clin Oncol 1984;2:782\u20137.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR36","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/0277-5379(86)90321-4","volume":"22","author":"R Saller","year":"1986","unstructured":"Saller R, Hellenbrecht D. High doses of metoclopramide or droperidol in the prevention of cisplatin induced emesis. Eur J Cancer Clin Oncol 1986;22: 1199\u2013203.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF01988874_CR37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0306-3623(88)90153-X","volume":"19","author":"MC Champion","year":"1988","unstructured":"Champion MC. Domperidone. Gen Pharmacol 1988;19: 499\u2013505.","journal-title":"Gen Pharmacol"},{"key":"BF01988874_CR38","first-page":"226","volume":"56","author":"D Cunningham","year":"1987","unstructured":"Cunningham D, Evans C, Pople A, et al. Comparison of the antiemetic efficacy of domperidone, MCP and Dex in out-patients receiving chemotherapy. Br J Cancer 1987;56:226.","journal-title":"Br J Cancer"},{"key":"BF01988874_CR39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/00000421-198810000-00017","volume":"11","author":"C Basurto","year":"1988","unstructured":"Basurto C, Roila F, Brocarda S, et al. A double blind trial comparing the antiemetic efficacy and toxicity of MCP versus MP versus domperidone in patients receiving doxorubicine chemotherapy. Am J Clin Oncol 1988;11:594\u20136.","journal-title":"Am J Clin Oncol"},{"key":"BF01988874_CR40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1185\/03007998509109611","volume":"9","author":"J Huys","year":"1985","unstructured":"Huys J, Troch M, Bourguignon RP, Smets PL. High dose alizapride versus high dose domperidone: a double blind comparative study in the management of cisplatin induced emesis. Curr Med Res Opin 1985;9:400\u20136.","journal-title":"Curr Med Res Opin"},{"key":"BF01988874_CR41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3109\/07357908809082115","volume":"6","author":"C Basurto","year":"1988","unstructured":"Basurto C, Roila F, Del Favero A. A prospective randomised double blind crossover study comparing the antiemetic effect of alizapride and metoclopramide in patients receiving cisplatin chemotherapy. Cancer Invest 1988;6:475\u20139.","journal-title":"Cancer Invest"},{"key":"BF01988874_CR42","first-page":"1301","volume":"69","author":"R Saller","year":"1985","unstructured":"Saller R, Hellenbrecht D. Comparison of the antiemetic efficacy of 2 high-dose benzamides, metoclopramide and alizapride, against cisplatin induced emesis. Cancer Treat Rep 1985;69:1301\u20132.","journal-title":"Cancer Treat Rep"},{"key":"BF01988874_CR43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/clpt.1986.109","volume":"39","author":"RA Joss","year":"1986","unstructured":"Joss RA, Galeazzi RL, Bischoff AL, et al. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy. Clin Pharmacol Ther 1986;39:619\u201324.","journal-title":"Clin Pharmacol Ther"},{"key":"BF01988874_CR44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bjc.1987.177","volume":"56","author":"WD Miner","year":"1987","unstructured":"Miner WD, Sanger GJ, Turner DH. Evidence that 5HT3 receptors mediate cytotoxic drug and radiationevoked emesis. Br J Cancer 1987;56:159\u201362.","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"BF01988874_CR45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2165\/00003495-198300251-00004","volume":"25","author":"OE Akwari","year":"1983","unstructured":"Akwari OE. The gastrointestinal tract in CIE. A final common pathway. Drugs 1983;25(Suppl 1):18\u201334.","journal-title":"Drugs"},{"key":"BF01988874_CR46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF00304763","volume":"24","author":"A Hamik","year":"1989","unstructured":"Hamik A, Peroutka SJ. Different interactions of traditional and novel antiemetics with dopamine D2 and 5HT3 receptors. Cancer Chemother Pharmacol 1989;24:307\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF01988874_CR47","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF00292931","volume":"12","author":"DE Withington","year":"1986","unstructured":"Withington DE. Dysrhythmias following intravenous metoclopramide. Intensive Care Med 1986;12:378\u20139.","journal-title":"Intensive Care Med"},{"key":"BF01988874_CR48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00000421-198906000-00012","volume":"12","author":"LB Tyson","year":"1989","unstructured":"Tyson LB, Gralla RJ, Kris MG, Young CW, Clark RA. Dose-ranging antiemetic trial of high-dose oral MCP. Am J Clin Oncol 1989;12:239\u201343.","journal-title":"Am J Clin Oncol"},{"key":"BF01988874_CR49","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/1097-0142(19871201)60:11<2816::AID-CNCR2820601137>3.0.CO;2-7","volume":"60","author":"MG Kris","year":"1987","unstructured":"Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anticancer therapy with lorazepam when used in combination with metoclopramide and dexamethasone. Cancer 1987;60:2816\u201322.","journal-title":"Cancer"},{"key":"BF01988874_CR50","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/1097-0142(19850201)55:3<527::AID-CNCR2820550310>3.0.CO;2-2","volume":"55","author":"MG Kris","year":"1985","unstructured":"Kris MG, Gralla RJ, Tyson LB, et al. Improved control of cisplatin induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Cancer 1985;55: 527\u201334.","journal-title":"Cancer"},{"key":"BF01988874_CR51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00299870","volume":"17","author":"S Frustaci","year":"1986","unstructured":"Frustaci S, Grattoni E, Tumolo S, et al. Randomised crossover antiemetic study in cisplatin treated patients. Cancer Chemother Pharmacol 1986;17:75\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF01988874_CR52","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/BF00262587","volume":"20","author":"SM Grunberg","year":"1987","unstructured":"Grunberg SM, McDermed JE, Bernstein L, Cohen JL. Examination of the correlation of serum MCP levels with antiemetic efficacy in patients receiving cisplatin. Cancer Chemother Pharmacol 1987;20:332\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF01988874_CR53","first-page":"330","volume":"8","author":"RA Clark","year":"1989","unstructured":"Clark RA, Gralla RJ, Kris MG, Tyson LB. Exploring very high dose of MCP (4\u20136 mg\/kg): preservation of efficacy and safety with only 1 single dose in a combination AE regimen. Proc ASCO 1989;8:330.","journal-title":"Proc ASCO"},{"key":"BF01988874_CR54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1200\/JCO.1986.4.1.98","volume":"4","author":"L Anthony","year":"1985","unstructured":"Anthony L, Krozeby M, Woodward, et al. Antiemetic efficacy of oral versus intravenous MCP in patients receiving cisplatin. J Clin Oncol 1985;4:98\u2013103.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR55","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000226638","volume":"45","author":"F Roila","year":"1988","unstructured":"Roila F, Basurto C, Minotti V, et al. MP versus MCP for prevention of nausea and vomiting in breast cancer patients treated with intravenous CMF. Oncology 1988;45:346\u20139.","journal-title":"Oncology"},{"key":"BF01988874_CR56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/j.1875-9114.1986.tb03465.x","volume":"6","author":"RT Cersosimo","year":"1986","unstructured":"Cersosimo RT, Karp DD. Adrenal corticosteroids as antiemetics during cancer chemotherapy. Pharmacotherapy 1986;6:118\u201327.","journal-title":"Pharmacotherapy"},{"key":"BF01988874_CR57","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/1097-0142(19891015)64:8<1595::AID-CNCR2820640807>3.0.CO;2-A","volume":"64","author":"JH Kearsley","year":"1989","unstructured":"Kearsley JH, Williams AM, Fiumara AM. Antiemetic superiority of lorazepam over oxazepam and methylprednisolone as premedicants for patients receiving cisplatin-containing chemotherapy. Cancer 1989;64: 1595\u20139.","journal-title":"Cancer"},{"key":"BF01988874_CR58","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1200\/JCO.1984.2.6.691","volume":"2","author":"JF Bishop","year":"1984","unstructured":"Bishop JF, Olver IN, Wolf MM, et al. Lorazepam: a randomised, double-blind, crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine. J Clin Oncol 1984;2:691\u20135.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR59","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/1097-0142(19890201)63:3<578::AID-CNCR2820630330>3.0.CO;2-Z","volume":"63","author":"CJ Gordon","year":"1989","unstructured":"Gordon CJ, Pasdur R, Zicarelli A, Cummings G, AlSarraf M. Metoclopramide versus metoclopramide and lorazepam. Cancer 1989;63:578\u201382.","journal-title":"Cancer"},{"key":"BF01988874_CR60","first-page":"334","volume":"9","author":"PLR Andrews","year":"1988","unstructured":"Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. TiPS 1988;9:334\u201341.","journal-title":"TiPS"},{"key":"BF01988874_CR61","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/330746a0","volume":"330","author":"GJ Kilpatrick","year":"1987","unstructured":"Kilpatrick GJ, Jones BJ, Tyers MB. Identification and distribution of 5HT-3 receptors in rat brain using radioligand binding. Nature 1987;330:746\u20138.","journal-title":"Nature"},{"key":"BF01988874_CR62","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.1989.7.8.1137","volume":"7","author":"SM Grunberg","year":"1989","unstructured":"Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dosing ranging phase I study of the serotonine antagonist GR38032F for prevention of cisplatin induced emesis. J Clin Oncol 1989;7:1137\u201341.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR63","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199003223221205","volume":"322","author":"M Marty","year":"1990","unstructured":"Marty M, Droz JP, Pouillart P, et al. Comparison of ondansetron with high-dose metoclopramide in the control of cisplatin induced emesis. N Engl J Med 1990;322:816\u201321.","journal-title":"N Engl J Med"},{"key":"BF01988874_CR64","unstructured":"Marty M, d'Allens H. A single dose of ondansetron is as effective as a continuous infusion in the prevention of cisplatin induced nausea and vomiting [Abstract]. XV ESMO Meeting; 1990 Dec 2\u20135; Copenhagen. W9:14."},{"key":"BF01988874_CR65","first-page":"137","volume":"24","author":"JA Green","year":"1989","unstructured":"Green JA, Watkin SW, Hammond P, Griggs J, Challoner T. Cancer Chemother Pharmacol 1989;24:137\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF01988874_CR66","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.1990.8.4.731","volume":"8","author":"LH Einhorn","year":"1990","unstructured":"Einhorn LH, Nagy C, Werner R, Finn AL. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 1990;8:731\u20135.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR67","volume-title":"Proc 6th NCI-EORTC symposium","author":"C Seynaeve","year":"1989","unstructured":"Seynaeve C, Van Liessum P, Lane-Allman E, DeMulder P, Verweij J. Control by GR38032F of acute and delayed nausea and vomiting induced by noncisplatin chemotherapy. Proc 6th NCI-EORTC symposium; 1989 datum, Amsterdam."},{"issue":"Suppl 1","key":"BF01988874_CR68","first-page":"15","volume":"26","author":"M Soukop","year":"1990","unstructured":"Soukop M. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990;26(Suppl 1):15\u20139.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"BF01988874_CR69","first-page":"33","volume":"26","author":"B Chevallier","year":"1990","unstructured":"Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single blind study. Eur J Cancer 1990;26(Suppl 1):33\u20136.","journal-title":"Eur J Cancer"},{"key":"BF01988874_CR70","first-page":"327","volume":"8","author":"L Stamatakis","year":"1989","unstructured":"Stamatakis L, Michel J, Van Belle S, et al. ICS205-930: a dose finding study in the prevention of cisplatin induced nausea and vomiting. Proc ASCO 1989;8:327.","journal-title":"Proc ASCO"},{"key":"BF01988874_CR71","unstructured":"Sorbe B, Frankendal B, Glimelius B, et al. A randomized study comparing the antiemetic efficacy of ICS 205-930 with a MCP-containing cocktail in patients receiving cisplatin treatment [Abstract]. XV ESMO Meeting; 1990 Dec 2\u20135; Copenhagen. W9:17."},{"key":"BF01988874_CR72","first-page":"338","volume":"9","author":"H Bleiberg","year":"1990","unstructured":"Bleiberg H, Dodion P, Piccart M, et al. Randomized double-blind crossover evaluation of batanopride versus placebo in patients receiving high-dose cisplatin. Proc ASCO 1990;9:338.","journal-title":"Proc ASCO"},{"key":"BF01988874_CR73","unstructured":"Smaldone L, Alberts D, Aapro M, et al. Randomized, double-blind crossover comparison of batanopride and MCP in patients receiving cisplatin based chemotherapy [Abstract]. XV ESMO Meeting; 1990 Dec 2\u20135; Copenhagen W9:2."},{"key":"BF01988874_CR74","first-page":"338","volume":"8","author":"F Roila","year":"1989","unstructured":"Roila F, Boschetti E, Tonato M, et al. Predictive factor of delayed emesis in cisplatin treated patients and antiemetic activity and tolerability of MCP and Dexa. A randomised single blind study. Proc ASCO 1989;8:338.","journal-title":"Proc ASCO"},{"key":"BF01988874_CR75","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1200\/JCO.1989.7.8.1142","volume":"7","author":"CM Lindley","year":"1989","unstructured":"Lindley CM, Bernard S, Fields. Incidence and duration of chemotherapy induced nausea and vomiting in the out-patient oncology population. J Clin Oncol 1989;7: 1142\u20139.","journal-title":"J Clin Oncol"},{"key":"BF01988874_CR76","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jnci\/80.11.864","volume":"80","author":"S Grunberg","year":"1988","unstructured":"Grunberg S, Ehler E, McDermed JE, Akerley WL. Oral metoclopramide with or without diphenhydramine:potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst 1988;80:864\u20138.","journal-title":"J Natl Cancer Inst"}],"container-title":["Pharmaceutisch Weekblad"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01988874.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01988874\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01988874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T21:40:45Z","timestamp":1557783645000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01988874"}},"subtitle":["An update"],"short-title":[],"issued":{"date-parts":[[1991,10]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1991,10]]}},"alternative-id":["BF01988874"],"URL":"https:\/\/doi.org\/10.1007\/bf01988874","relation":{},"ISSN":["0031-6911","1573-739X"],"issn-type":[{"value":"0031-6911","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,10]]}}}